MannKind Corporation Common Stock (MNKD)
Fast GrowerFairStock Score: 29/100 — RISKY
Key Financials
| Current Price | $3.09 |
| Market Cap | $831M |
| P/E Ratio | -44.14 |
| ROE | —% |
| Dividend Yield | —% |
| Sector | Healthcare |
Strengths
- Generates $47 million in annual free cash flow (5.7% yield on market cap)
- Revenue growth of 45.8% demonstrates strong top-line momentum
Concerns
- Elevated P/E of 178.0x prices in substantial future growth that may not materialize
- Currently unprofitable—sustained losses could lead to dilutive capital raises or balance sheet deterioration
- Weak Piotroski F-Score of 1/9 suggests deteriorating financial quality across multiple dimensions
- Altman Z-Score of -4.8 places it in the financial distress zone—elevated bankruptcy risk
AI Analysis
MannKind Corporation Common Stock is a micro-cap healthcare company valued at $831 million. Revenue stands at $361 million, though the company is currently unprofitable. From a quality standpoint, MannKind shows weak Piotroski F-Score of 1/9 signaling deteriorating fundamentals and distressed Altman Z-Score of -4.8 warrants caution. On valuation, the stock is commanding a steep 178.0x multiple. Growth dynamics show revenue growing at 45.8% and profit growth of -314.9%. Our composite FairStock Score of 29/100 reflects below-average fundamentals overall. Without profitability, this remains speculative—suitable only for those with high risk tolerance and a long time horizon.
Bull Case
MannKind's 46% revenue growth trajectory could accelerate as it captures additional market share in the healthcare sector. With $47 million in annual free cash flow (5.7% yield), management has ample capital for buybacks, dividends, or accretive acquisitions.
Bear Case
At 178x earnings, any growth disappointment triggers rapid multiple compression—a 20% earnings miss plus multiple contraction to 20x implies 40%+ downside. Regulatory changes, input cost inflation, or demand normalization represent underappreciated risks that could materially impact forward estimates.
Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer